Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences to Focus Solely on Research and Development of Therapeutics Targeting Addiction

Newsfile June 9, 2023

Canadian Investment Regulatory Organization Trading Halt - AWKN

Canada NewsWire June 9, 2023

Awakn Life Sciences Reports Q4 2023 and Annual Results

Newsfile April 28, 2023

IIROC Trade Resumption - AWKN

Canada NewsWire April 26, 2023

Awakn Life Sciences Announces Private Placement

Newsfile April 26, 2023

IIROC Trading Halt - AWKN

Canada NewsWire April 26, 2023

Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial

Newsfile April 18, 2023

Awakn Life Sciences Increases Ownership of Awakn Bristol to 100% and Provides Corporate Update

Newsfile April 12, 2023

Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California

Newsfile February 28, 2023

Awakn Life Sciences (NEO:AWKN) signs first licensing agreement in Europe

John Ballem  February 22, 2023

Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe

Newsfile February 21, 2023

Awakn Life Sciences Announces the Opening of Its Fourth Clinic

Newsfile February 14, 2023

Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology

Newsfile February 9, 2023

Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity

Newsfile February 8, 2023

Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder

Newsfile February 7, 2023

Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect

Newsfile January 24, 2023

Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

Newsfile December 15, 2022

Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)

Newsfile December 13, 2022

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Newsfile December 1, 2022

Awakn Life Sciences Announces Location for Larger Oslo Clinic

Newsfile November 23, 2022